Antibody modulation: Limiting the efficacy of therapeutic antibodies
نویسندگان
چکیده
منابع مشابه
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success, a substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence more potent anti-CD20 monoclonal antibodies (mAbs) are continuously being sought. Here we demonstrate that type II (tositumomab-like) ant...
متن کاملInternalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.
Direct experimental proof has been sought for the hypothesis that liposomal drugs targeted against internalizing epitopes (e.g., CD19) will have higher therapeutic efficacies than those targeted against noninternalizing epitopes (e.g., CD20). Anti-CD19-targeted liposomes were rapidly internalized into human B-lymphoma (Namalwa) cells, whereas those targeted with anti-CD20 were not internalized....
متن کاملTherapeutic Applications of Monoclonal Antibodies in Multiple Sclerosis
Despite the various therapies available, the use of monoclonal antibodies is a highly specific approach that has only recently been of interest to researchers. The properties of antibodies have led to their use in the treatment of various diseases, including cancer, Alzheimer's disease, diabetes and multiple sclerosis (MS). MS, a chronic inflammatory disease, occurs commonly in young adults. Th...
متن کاملThe rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies.
The rabbit antibody repertoire, which in the form of polyclonal antibodies has been used in diagnostic applications for decades, would be an attractive source for the generation of therapeutic human antibodies. The humanization of rabbit antibodies, however, has not been reported. Here we use phage display technology to select and humanize antibodies from rabbits that were immunized with human ...
متن کاملTreating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting.
The clinical trial reported by Hartmann et al. later in this issue of Clinical Cancer Research represents a triumph of clinical research conducted in a rare patient population with a limited quantity of a therapeutic reagent. Despite the fact that Hodgkin’s disease is an uncommon cancer, i.e., only 7100 cases were diagnosed in the United States in 1998, it has been a model for therapeutic advan...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacological Research
سال: 2015
ISSN: 1043-6618
DOI: 10.1016/j.phrs.2015.07.003